ilico genetics

Ilico Genetics is a small biotechnology company based in the United States, employing four individuals. The company was spun off from Pontificia Universidad Católica de Chile, leveraging its research foundation to develop innovative healthcare solutions. Ilico Genetics specializes in the development of molecular tests for early gastric cancer detection. Their flagship product utilizes methylated DNA analysis from a simple blood sample to identify tumors or pre-cancerous lesions in the stomach, even years before symptoms appear. This diagnostic tool aims to provide an early warning system for gastric cancer, enabling timely intervention and potentially life-saving treatment. The company's unique approach relies on analyzing methylated DNA, a biomarker associated with tumor development. Their test offers a non-invasive alternative to traditional methods like Esophagogastroduodenoscopy (EGD), which requires endoscopy procedures. Ilico Genetics' test also provides dynamic results, tracking the cumulative presence of tumors over time, allowing for continuous monitoring and informed medical decisions. For inquiries or further information, please visit Ilico Genetics' website at ilicogenetics.com.